Drug interchangeability: Clinical approach and consumer's point of view

Revista de Saude Publica

Volumn 40, Issue 5, 2006, Pages 921-927

  Rumel, Davi ^a   Nishioka, Sérgio de Andrade ^a   dos Santos, Adélia Aparecida Marçal ^a  

^a Agencia Nacional de Vigilancia Sanitaria Brazil   (Brazil)

Author keywords

Drug utilization; Drugs, generic; Physician self referral, ethics; Prescriptions, drug; Similar drugs

Indexed keywords

GENERIC DRUG;

ARTICLE; CLINICAL PRACTICE; CONSUMER; ETHICS; HUMAN; PHARMACOKINETICS; PRACTICE GUIDELINE; REFERENCE VALUE; STANDARD;

CONSUMER SATISFACTION; DRUGS, GENERIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; REFERENCE VALUES; THERAPEUTIC EQUIVALENCY;

EID: 34247116564     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-89102006000600024     Document Type: Note

References (18)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. JAMA. 2002:288:2981-97.
2. Arias TD. Glosario de medicamentos: desarollo, evaluacion y uso. Washington (DC): Organización Panamericana de la Salud; 1999.
3. Berne C, Siewert-Delle A, URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc diabetol. 2005;4:7.
4. Bovier PA, Farinelli T, Loutan L. Intercgangeability and tolerability of a virosomal and an aluminium-absrbed hepatitis A vaccine. Vaccine. 2005;23:2424-9.
5. Carter BL, Ernst ME, Cohen JD. Hydroclorothiazide versus chlorthalidone, evidence supporting their interchangerability. Hypertension. 2004;43:4-9.
6. Chong PH. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Ann Pharmacother. 2002;36:1907-17.
7. Crommelin D, Bermejo T, Bissig M, Damiaans J, Kramer I, Rambourg P, et al. Biosimilar, generic versions of the first generation of therapeutic proteins: do they exist? Contrib Nephrol. 2005;149:287-94.
8. David-Neto E, Kakehashi E, Alves CF, Pereira LM, Castro MCR, Mattos RM, et al. Bioequivalence of a new cyclosporine A formulation to Neoral. Ther Drug Monit. 2004;26:53-7.
9. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill: pharmacology, pharmacodynamics and available formulations. Ann Pharmacother. 2005;39:1667-77.
10. Feldman S. Interchangeability of vaccines. Pediatr Infect Dis J. 2001;20(11 Suppl):S23-9.
11. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet. 1999;354(9185):1202-4.
12. Hennekens CH, Buring JE. Issues in interpreting results of tests of statistical significance. In: Hennekens CH, Buring JE. Epidemiology in medicine. Boston (MA): Little, Brown; 1987. p. 257-8.
13. Lam YWF, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine: bioavailability comparisos and interchangeability issues. J Clin Psychiatry. 2001;62 Suppl 5:18-22.
14. Maitland-van der Zee AH, Boer A, Leufkens HGM. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol. 2000;410(2-3):121-30.
15. Organização Mundial da Saúde. Guia para a boa prescrição médica. Porto Alegre: Artmed; 1988.
16. Palylyk-Colwell E, Jamali F, Dryden W, Friesen E, Koven S, Mohamed I, et al. Bioequivalence and interchangeability of narrow therapeutic range drugs: Canadian Society for Pharmaceutical Sciences discussion. J Pharm Pharm Sci. 1998;1:2-7.
17. Vercaigne LM, Zhanel GG. Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on wafarins. J Pharm Pharm Sci. 1998;1(3):92-4.
18. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004;5:995-8.